Dr. Wei Phin Tan, MD, MHS, FACS, is a board-certified urologic oncologist at NYU Langone Health specializing in prostate cancer treatment in NYC. He provides comprehensive prostate cancer care, including active surveillance, focal therapy, precision robotic prostatectomy, and prostate rectal spacer placement before radiation therapy, including CyberKnife and other forms of precision radiation. Dr. Tan places spacers such as SpaceOAR and Barrigel to help reduce radiation exposure to the rectum in appropriately selected patients. Because he performs and coordinates the full range of prostate cancer treatment options, Dr. Tan helps patients choose the approach that best fits their cancer, anatomy, treatment goals, and quality-of-life priorities, rather than defaulting to a single treatment modality.
A full spectrum of treatment options, no single-specialty bias. Dr. Tan matches each patient to the approach that fits their cancer, their anatomy, and their life.
Services are organized by cancer type. Most patients start with Where to Start below, then explore the section that matches their diagnosis: prostate, bladder & upper tract, or kidney.
Most prostate cancer decisions are not urgent. The right starting point is often surveillance or an independent second opinion.
Structured monitoring for low-risk and favorable intermediate-risk prostate cancer with PSA, MRI, and protocolized transperineal biopsy.
Learn more →Independent review of PSA, MRI, biopsy, and any proposed plan from a urologic oncologist who performs the full spectrum of treatments.
Learn more →Focal therapy, robotic surgery, and radiation preparation, all by the same surgeon.
High-intensity focused ultrasound via the Focal One machine. Incisionless, organ-sparing, outpatient procedure under general anesthesia.
Learn more →Cryoprobes placed transperineally to freeze the cancer-bearing region. Primary and salvage cryoablation for radio-recurrent disease.
Learn more →Pulsed electric field ablation, non-thermal focal therapy. First surgeon at NYU Langone and in Manhattan to perform Aliya PEF.
Learn more →Long urethral-sparing technique. Same-day discharge for most. Catheter removal at day 5.
Learn more →500+ per year, office-based under local anesthesia. Published low pain scores. Near-zero infection risk.
Learn more →Office Barrigel and SpaceOAR rectal spacers, gold fiducial markers for CyberKnife, MR-Linac, and IGRT.
Learn more →TURBT, intravesical therapy, robotic cystectomy, and kidney-sparing UTUC management.
Blue light cystoscopy plus BCG, BRIDGE gem-doce, Anktiva, Adstiladrin, Keytruda, Inlexzo, and Zusduri.
Learn more →Robotic cystectomy with intracorporeal ileal conduit or orthotopic neobladder. Published peer-reviewed work on intracorporeal technique.
Learn more →Robotic nephroureterectomy plus endoscopic kidney-sparing options and Jelmyto for low-grade UTUC.
Learn more →Robotic partial and radical nephrectomy, including complex cases with caval thrombus.
The full spectrum of urologic oncology, from active surveillance to focal therapy to robotic surgery, under one surgeon.
Focal therapy, robotic surgery, radiation preparation (rectal spacers and fiducials), and active surveillance, all performed and discussed by the same surgeon. Less vested interest in any one approach means the right treatment for the right patient. The goal is to match the treatment to the patient, not the patient to the treatment.
Contributions to the evidence base on focal therapy, transperineal biopsy, kidney surgery, and bladder cancer. NCI Ruth L. Kirschstein NRSA Grant recipient.
Subspecialty training in prostate, kidney, bladder, and testicular cancers, plus a Master of Health Science in Clinical Research Methods.
The right treatment for the right patient, not the most aggressive one, not the trendiest one. Shared decisions grounded in your anatomy, cancer biology, and priorities.
“Not every prostate cancer needs aggressive treatment. Some men can safely live with their cancer for years. The key is knowing which cancers can be watched, and which cancers need treatment so they do not become life-threatening.”- Dr. Wei Phin Tan, MD, MHS, FACS
A selection of current research efforts spanning industry-sponsored trials, cooperative group studies, and investigator-initiated research in prostate, kidney, and bladder cancer.
Randomized Phase III cooperative-group trial comparing standard BCG to combination chemotherapy (gemcitabine + docetaxel) in newly diagnosed high-grade NMIBC. Open to accrual since August 2023.
Evaluating next-generation PSMA PET/MRI imaging to detect prostate cancer recurrence with greater accuracy after HIFU focal therapy.
Examining real-world prostate cancer screening patterns at NYU to identify gaps and improve early detection in diverse patient populations.
Clinical trial evaluating the BARRigel rectal spacer to enhance the safety and oncologic outcomes of prostate cryoablation.
IRB-approved institutional database tracking outcomes and clinical data from MRI-targeted prostate biopsies, informing best practices for diagnostic accuracy and patient safety.
In-development investigator-initiated study evaluating real-time intraoperative margin imaging to refine surgical precision. Currently in IRB submission (April 2026); not yet enrolling.
Recent coverage of Dr. Tan's research and contributions to urologic oncology.
Dr. Tan is a co-author on this NYU Langone early pilot study detecting higher microplastic concentrations in prostate tumor tissue than adjacent noncancerous tissue. The findings are exploratory and do not establish causation.
Read article →Dr. Tan discusses prostate cancer treatment and his approach to personalized urologic oncology care at NYU Langone's Perlmutter Cancer Center.
Watch interview →Dr. Tan featured discussing healthcare policy and prostate cancer care access for U.S. military veterans.
Read article →Recognized at urology congresses across four continents for contributions to prostate cancer, focal therapy, and surgical research.
When you're a hammer, everything looks like a nail. But patients are not nails, and treatments are not one-size-fits-all. My job is to step back, understand the patient and the cancer, and match the right treatment to the right patient, not force the patient to fit a single treatment.
A new diagnosis, or a recommendation you're uncertain about, deserves a careful second look. Because Dr. Tan performs focal therapy, robotic prostatectomy, and monitors active surveillance patients, his review considers every appropriate option, not just the ones a single-modality specialist offers.
Request a Second Opinion
NYU Langone Health, Main Campus
222 E 41st Street, 12th Floor
New York, NY 10017
Phone:
646-825-6300
Hours: Mon–Fri, 9am–5pm
Consultations are available for prostate cancer, kidney cancer, bladder cancer, elevated PSA, and second opinions. Insurance participation varies by plan and location, please confirm coverage with NYU Langone and your insurer before scheduling.
Book Online